Non-Sterile Compounding Pharmacy Market – U.S. & Europe Forecast Till 2027

Non-Sterile Compounding Pharmacy Market Information: By-Product (Oral Medication, Topical Medication, Otologic/Nasal Medication), Application (Pain Medication, Hormone Replacement Therapy), End User (Compounding Pharmacy) – U.S. & Europe Forecast till 2027

ID: MRFR/Pharma/3248-CR | October 2017 | Region: Global | 101 Pages         

1 Report Prologue

2 Market Introduction

2.1 Definition 15

2.2 Scope of the Study 15

2.2.1 Research Objective 15

2.2.2 Assumptions 15

2.2.3 Limitations 15

3 Research Methodology

3.1 Introduction 17

3.2 Primary Research 18

3.3 Secondary research 18

3.4 Market Size Estimation 19

4 Market Dynamics

4.1 Introduction 21

4.2 Drivers 22

4.2.1 Increasing prevalence of chronic diseases (Impact weightage-35%) 23

4.2.2 Increasing need for customized medicine (Impact weightage-25%) 24

4.2.3 No availability of the alternative methods (Impact weightage-20%) 25

4.2.4 Increasing Geriatric Population (Impact weightage-20%) 26

4.3 Restrains 27

4.3.1 Poor reimbursement policies (Impact weightage-60%) 28

4.3.2 Strict Regulatory Rules (Impact weightage-40%) 29

4.4 Mega Trends 30

4.5 Opportunity 31

4.6 Macroeconomic indicators 31

5 Market Factor Analysis

5.1 Supply/Value Chain 32

5.1.1 Research & Development 32

5.1.2 Formulation 32

5.1.3 Marketing & Sales 32

5.1.4 Finish Products 33

5.2 Porters Five forces Model 33

5.2.1 Bargaining Power Of Suppliers 34

5.2.2 Bargaining Power Of Buyers 34

5.2.3 Threat Of New Entrants 34

5.2.4 Threat Of Substitutes 34

5.2.5 Intensity Of Rivalry 34

5.3 Investment Opportunity Analysis 35

5.4 Demand & Supply: Gap Analysis 35

5.5 Pricing Analysis 36

6 U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

6.1 Introduction 37

6.2 Oral Medication 39

6.3 Topical Medications 42

6.4 Otologic/Nasal Medication 43

7 U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

7.1 Introduction 44

7.2 Pain management 44

7.3 Hormone Replacement Therapy 45

8 U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

8.1 Introduction 47

8.2 Hospital 48

8.3 Compounding Pharmacy 48

9 U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Region

9.1 Introduction 49

9.2 U.S. 50

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.2.1 U.S. 51

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3 Europe 56

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.1 Western Europe 62

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.2 Germany 65

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.3 France 68

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.4 U.K. 71

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.5 Italy 74

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.6 Spain 77

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.7 The Netherlands 80

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.8 Rest of Western Europe 83

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

9.3.9 Eastern Europe 86

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Product

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By Application

U.S. & Europe Non- Sterile Compounding Pharmacy Market, By End User

10 Company Landscape

10.1 Introduction: Key Players 90

10.2 Key Developments and Strategies 91

11 Company Profiles

11.1 Fagron 92

11.1.1 Company Overview 92

11.1.2 Financials 92

11.1.3 Products 92

11.1.4 Strategy 92

11.1.5 Key Developments 92

11.2 B.Braun Melsungen AG 93

11.2.1 Company Overview 93

11.2.2 Financials 93

11.2.3 Products 93

11.2.4 Strategy 93

11.2.5 Key Developments 93

11.3 Fresenius Kabi AG 94

11.3.1 Company Overview 94

11.3.2 Financials 94

11.3.3 Products 94

11.3.4 Strategy 94

11.3.5 Key Developments 94

11.4 True Nature Holding, Inc 95

11.4.1 Company Overview 95

11.4.2 Financials 95

11.4.3 Products 95

11.4.4 Strategy 95

11.4.5 Key Developments 95

11.5 Dougherty's Pharmacy, Inc. 96

11.5.1 Company Overview 96

11.5.2 Financials 96

11.5.3 Products 96

11.5.4 Strategy 96

11.5.5 Key Developments 96

11.6 Pharmedium 97

11.6.1 Company Overview 97

11.6.2 Financials 97

11.6.3 Products 97

11.6.4 Strategy 97

11.6.5 Key Developments 97

12 MRFR Conclusion

12.1 Key Findings 98

12.1.1 From CEO’s View Point 98

12.1.2 Unmet Needs 98

12.2 Key companies to watch 98


13 Appendix

13.1 Discussion Blue Print 99

14 List of Tables

TABLE 1 U.S. & EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2020- 2027 (USD MILLION) 39

TABLE 2 U.S. & EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET FOR ORAL MEDICATIONS,

BY REGION, 2020-2027 (USD MILLION) 41

TABLE 3 U.S. & EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET FOR TOPICAL MEDICATIONS,

BY REGION, 2020-2027 (USD MILLION) 42

TABLE 4 U.S. & EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET FOR OTOLOGIC/

NASAL MEDICATION, BY REGION, 2020-2027 (USD MILLION) 43

TABLE 5 U.S. & EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2020-2027 (USD MILLION) 45

TABLE 6 U.S. & EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER,

2020-2027 (USD MILLION) 48

TABLE 7 U.S. & EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY REGION,

2020-2027 (USD MILLION) 49

TABLE 8 U.S. NON- STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2020-2027 (USD MILLION) 51

TABLE 9 U.S. LIQUID PREPARATION MARKET, BY VOLUME, 2020-2027 (UNITS) 51

TABLE 10 U.S. SYRUPS MARKET, BY VOLUME, 2020-2027 (UNITS) 51

TABLE 11 U.S. SOLUTION MARKET, BY VOLUME, 2020-2027 (UNITS) 51

TABLE 12 U.S. SUSPENSION MARKET, BY VOLUME, 2020-2027 (UNITS) 52

TABLE 13 U.S. LIQUID PREPARATION MARKET, BY COMPANY WISE VOLUME 52

TABLE 14 U.S. NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT , 2020-2027 (USD MILLION) 52

TABLE 15 U.S. NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2020-2027 (USD MILLION) 53

TABLE 16 U.S. NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2020-2027 (USD MILLION) 53

TABLE 17 U.S. NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2020-2027 (USD MILLION) 54

TABLE 18 U.S. NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 54

TABLE 19 U.S. NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER, 2020-2027 (USD MILLION) 55

TABLE 20 EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY REGION, 2020-2027 (USD MILLION) 57

TABLE 21 EUROPE LIQUID PREPARATION MARKET, BY VOLUME, 2020-2027 (UNITS) 57

TABLE 22 EUROPE SYRUPS MARKET, BY VOLUME, 2020-2027 (UNITS) 57

TABLE 23 EUROPE SOLUTION MARKET, BY VOLUME, 2020-2027 (UNITS) 58

TABLE 24 EUROPE SUSPENSION MARKET, BY VOLUME, 2020-2027 (UNITS) 58

TABLE 25 EUROPE LIQUID PREPARATION MARKET, COMPANY WISE VOLUME 58

TABLE 26 EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 59

TABLE 27 EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2020-2027 (USD MILLION) 59

TABLE 28 EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2020-2027 (USD MILLION) 60

TABLE 29 EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2020-2027 (USD MILLION) 60

TABLE 30 EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2020-2027 (USD MILLION) 61

TABLE 31 EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER, 2020-2027 (USD MILLION) 61

TABLE 32 WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2020-2027 (USD MILLION) 62

TABLE 33 WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2020-2027 (USD MILLION) 62

TABLE 34 WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2020-2027 (USD MILLION) 63

TABLE 35 WESTERN EUROPE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2020-2027 (USD MILLION) 63

TABLE 36 WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2020-2027 (USD MILLION) 64

TABLE 37 WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER,

2020-2027 (USD MILLION) 64

TABLE 38 GERMANY NON- STERILE COMPOUNDING PHARMACY MARKET, BY VOLUME, 2020-2027 (UNITS) 65

TABLE 39 GERMANY NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 65

TABLE 40 GERMANY NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2020-2027 (USD MILLION) 66

TABLE 41 GERMANY NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2020-2027 (USD MILLION) 66

TABLE 42 GERMANY NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2020-2027 (USD MILLION) 67

TABLE 43 GERMANY NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2020-2027 (USD MILLION) 67

TABLE 44 GERMANY NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER, 2020-2027 (USD MILLION) 68

TABLE 45 FRANCE NON- STERILE COMPOUNDING PHARMACY MARKET, BY VOLUME, 2020-2027 (UNITS) 68

TABLE 46 FRANCE NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 68

TABLE 47 FRANCE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2020-2027 (USD MILLION) 69

TABLE 48 FRANCE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2020-2027 (USD MILLION) 69

TABLE 49 FRANCE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2020-2027 (USD MILLION) 70

TABLE 50 FRANCE NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 70

TABLE 51 FRANCE NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER, 2020-2027 (USD MILLION) 71

TABLE 52 U.K. NON- STERILE COMPOUNDING PHARMACY MARKET, BY VOLUME, 2020-2027 (UNITS) 71

TABLE 53 U.K. NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 71

TABLE 54 U.K. NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2020-2027 (USD MILLION) 72

TABLE 55 U.K. NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2020-2027 (USD MILLION) 72

TABLE 56 U.K. NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2020-2027 (USD MILLION) 73

TABLE 57 U.K. NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 73

TABLE 58 U.K. NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER, 2020-2027 (USD MILLION) 74

TABLE 59 ITALY NON- STERILE COMPOUNDING PHARMACY MARKET, BY VOLUME, 2020-2027 (UNITS) 74

TABLE 60 ITALY NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 74

TABLE 61 ITALY NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2020-2027 (USD MILLION) 75

TABLE 62 ITALY NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2020-2027 (USD MILLION) 75

TABLE 63 ITALY NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2020-2027 (USD MILLION) 76

TABLE 64 ITALY NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 76

TABLE 65 ITALY NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER, 2020-2027 (USD MILLION) 77

TABLE 66 SPAIN NON- STERILE COMPOUNDING PHARMACY MARKET, BY VOLUME, 2020-2027 (UNITS) 77

TABLE 67 SPAIN NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT, 2020-2027 (USD MILLION) 77

TABLE 68 SPAIN NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2020-2027 (USD MILLION) 78

TABLE 69 SPAIN NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2020-2027 (USD MILLION) 78

TABLE 70 SPAIN NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/NASAL MEDICATIONS,

2020-2027 (USD MILLION) 79

TABLE 71 SPAIN NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION, 2020-2027 (USD MILLION) 79

TABLE 72 SPAIN NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER, 2020-2027 (USD MILLION) 80

TABLE 73 THE NETHERLANDS NON- STERILE COMPOUNDING PHARMACY MARKET, BY VOLUME, 2020-2027 (UNITS) 80

TABLE 74 THE NETHERLANDS NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2020-2027 (USD MILLION) 80

TABLE 75 THE NETHERLANDS NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2020-2027 (USD MILLION) 81

TABLE 76 THE NETHERLANDS NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2020-2027 (USD MILLION) 81

TABLE 77 THE NETHERLANDS NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/

NASAL MEDICATIONS, 2020-2027 (USD MILLION) 82

TABLE 78 THE NETHERLANDS NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2020-2027 (USD MILLION) 82

TABLE 79 THE NETHERLANDS NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER,

2020-2027 (USD MILLION) 83

TABLE 80 REST OF WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCTS,

2020-2027 (USD MILLION) 83

TABLE 81 REST OF WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR

TOPICAL MEDICATIONS, 2020-2027 (USD MILLION) 84

TABLE 82 REST OF WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET,

FOR ORAL MEDICATIONS, 2020-2027 (USD MILLION) 84

TABLE 83 REST OF WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET,

FOR OTOLOGIC/NASAL MEDICATIONS, 2020-2027 (USD MILLION) 85

TABLE 84 REST OF WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2020-2027 (USD MILLION) 85

TABLE 85 REST OF WESTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER,

2020-2027 (USD MILLION) 86

TABLE 86 EASTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2020-2027 (USD MILLION) 86

TABLE 87 EASTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR TOPICAL MEDICATIONS,

2020-2027 (USD MILLION) 87

TABLE 88 EASTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR ORAL MEDICATIONS,

2020-2027 (USD MILLION) 87

TABLE 89 EASTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, FOR OTOLOGIC/

NASAL MEDICATIONS, 2020-2027 (USD MILLION) 88

TABLE 90 EASTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2020-2027 (USD MILLION) 88

TABLE 91 EASTERN EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY END USER,

2020-2027 (USD MILLION) 89

TABLE 92 KEY DEVELOPMENTS AND STRATEGIES 91

15 List of Figures

FIGURE 1 U.S. & EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT MARKET SHARE,

2020 (%) 13

FIGURE 2 U.S. & EUROPE NON- STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION, MARKET SHARE

2020 (%) 13

FIGURE 3 U.S. AND EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET BY END USER, MARKET SHARE

2020 (%) 14

FIGURE 4 MARKET STRUCTURE 16

FIGURE 5 RESEARCH PROCESS 17

FIGURE 6 FORECAST MODEL 20

FIGURE 7 VALUE CHAIN:NON-STERILE COMPOUNDING PHARMACY MARKET 32

FIGURE 8 PORTERS FIVE FORCES MODEL 33

FIGURE 9 U.S. & EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET, BY PRODUCT,

2020 & 2027 (USD MILLION) 38

FIGURE 10 U.S. & EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET, BY APPLICATION,

2020- 2027 (USD MILLION) 46

FIGURE 11 U.S. & EUROPE NON-STERILE COMPOUNDING PHARMACY MARKET: COMPANY SHARE ANALYSIS

FOR THE KEY PLAYERS, 2020 (%) 90

Market Synopsis of the U.S. & Europe Non-Sterile Compounding Pharmacy Market


The U.S. Pharmacopeia Convention (USP) formally defines compounding as ‘the preparation, mixing, assembling, altering, packaging, and labelling of a drug, drug-delivery device in accordance with a licensed practitioner's prescription, medication order, or initiative based on the practitioner/patient/ pharmacist/compounder relationship in the course of professional practice.’ Products manufactured by a compounding pharmacy are customized according to the patient need.


The market for non-sterile compounding pharmacy is driven by an increasing prevalence of chronic diseases such as diabetes, rising need for customized medicine and increasing geriatric population. Furthermore, the demand for anti-aging products that use custom compounded drugs is growing in the U.S. and Europe. However, the strict regulations governing the manufacturing of the compounded product and high prices restrain the market growth.


The U.S. & Europe non-sterile compounding pharmacy market is expected to grow steadily at a CAGR of 2.65% during the forecast period.


FIGURE 1: U.S. & Europe Non-sterile Compounding Pharmacy Market by Application, 2016 (%) Non-Sterile Compounding Pharmacy Market Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Key Players in the U.S. & Europe non-sterile compounding pharmacy market


Fagron (the Netherlands), B.Braun Melsungen AG (Germany), Fresenius Kabi AG (Germany), TRUE NATURE HOLDING, INC (U.S), Dougherty's Pharmacy Inc. (U.S.) and PHARMEDIUM (U.S.).


Segments


The U.S. & Europe non-sterile compounding pharmacy market is segmented into product, application, and end user.


By type, the market is segmented into oral medication, topical medication, otologic/nasal medication, and others. The oral medications are further segmented into solid and liquid preparations. The topical medications include ointments, creams, gels, pastes, and others.


By application, the Non-Sterile Compounding Pharmacy Market is segmented into pain medication, hormone replacement therapy, and others.


By end user, the market is segmented into hospitals, compounding pharmacy and others.


Key Findings:



  • Pain management is expected to account for the largest market share of 50.3% in the U.S. and Europe non-sterile compounding pharmacy market

  • Hospitals occupy the largest market share and is expected to reach USD 871.97 million by 2023.


Research Methodology Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Research Methodology Non-Sterile Compounding Pharmacy Market- Source: World Health Organization, Centers for Disease Control and Prevention, European Society of Clinical Microbiology and Infectious Diseases, U.S. National Library of Medicine, National Organization for Rare Disorders, The American Autoimmune Related Diseases Association, The International Society for Human and Animal Mycology, Expert Interview Market Research Future Analysis, Annual report, White paper, Company Presentation


Intended Audience



  • Compounding pharmacy

  • Hospitals

  • Medical Research Laboratories

  • Research and Development (R&D) Companies

  • Market Research and Consulting Service Providers

  • Potential Investors


Regional Analysis of the Non-Sterile Compounding Pharmacy Market             


America is holding the first position in the Non-Sterile Compounding Pharmacy Market owing to the rising demand for customized medicine, increasing prevalence of chronic diseases such as diabetes, and rising number of hospital-based compounding pharmacies. As per the Center for Diseases Control and Prevention (CDC) in 2015, 30.3 million Americans, i.e. 9.4% of the population had diabetes. Additionally, 1.25 million American children and adults had type 1 diabetes.


Europe is the second largest non-sterile compounding pharmacy market across the globe. In Europe, growing awareness about compounding pharmaceutical products for the treatment of chronic diseases such as diabetes, drug allergies, and increasing number of prescriptions for the compounded medications propel the growth of the market. According to the European Academy of Allergy and Clinical Immunology (EAACI), around 2.6% hospitalization happens due to adverse drug effects, while the prevalence of drug allergy in the hospitalized patients is about 10% in the Europe.



Speak to Analyst Ask for Customization